banner
ERK inhibitor XMD 17-109, Purity ≥98%
Inquiry

Cat. No.: X23-10-ZQ869

ERK inhibitor XMD 17-109, Purity ≥98%

Synonym: XMD17-109; 1435488-37-1; 11-Cyclopentyl-2-[2-ethoxy-4-[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]anilino]-5-methylpyrimido[4,5-b][1,4]benzodiazepin-6-one; XMD17109; 11-Cyclopentyl-2-((2-ethoxy-4-(4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl)phenyl)amino)-5-methyl-5,11-dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one; ERK inhibitor

  • CAS Number: 1435488-37-1
  • Compound CID: 71604307
img
Product Size
5 mg; 10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
XMD 17-109, soluble in DMSO and ethanol and insoluble in water, exhibits potent inhibition of ERK kinase. It targets ERK5.
Molecular Weight
638.8
Molecular Formula
C36H46N8O3
Targets
ERK5: 162 nM
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 97 mg/mL (151.84 mM); Water: Insoluble; Ethanol: 97 mg/mL
Identity
Confirmed by NMR/HPLC/MS.
Applications
XMD 17-109 can be applied to the study of ERK1/2 inhibition in cancer biology and therapy.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0